Problem and Solution

Almost all cancer deaths with solid tumor disease are caused by metastatic disease - the spread of cancer from its original location to distant areas within the body.  Once a primary tumor has spread, traditional treatments of surgery and radiation offer little hope for true recovery and quality of life. For many types of cancer, traditional chemotherapy is relatively ineffective, and death rates remain high for individuals with metastatic disease.

In response to the problem CureMeta developed a unique antibody-drug development platform to generate highly specific and high-affinity monoclonal antibodies to embryonic protein and carbohydrate structures which are targets for aggressive and metastatic cancers. Learn More

Target and Antibody

Our lead cancer target, TRA-1-60 is highly present in normal human embryonic stem cells during embryogenesis. This large carbohydrate molecule disappears when embryonic stem cells differentiate into somatic cells.

As a way to attack the cancer, we have developed a proprietary antibody-discovery platform to generate monoclonal antibodies, to novel and untested cancer targets. We used Bstrongximab to generate a powerful antibody-drug-conjugate, CM-09, which targets and kills gastric and pancreatic cancer. Learn More

Clinical Trials

We are transitioning from a preclinical to a clinical biotech and preparations are underway to take CM-09 into a human clinical cancer trial. During this next step, we will complete a human clinical phase 1 trial to generate safety and efficacy data in patients with these metastatic cancers. We anticipate minimal toxicity in the trial because the cancer target TRA-1-60 is not found in normal healthy tissues. Currently, there are no effective cancer treatments that offer any meaningful benefits or quality of life to patients suffering from these metastatic cancers. CM-09 has the potential to be a first-in-class cancer treatment to change the outlook for patients with metastatic cancers.